Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
2 additional source qualifications - review before use
The adult no-adjustment passage does not extend below its studied clearance boundary. The IV vehicle adds a separate accumulation concern that is not the same as an oral dose adjustment.
Before applying: Retain the lower-function evidence limit, exact formulation and kidney monitoring together. Do not convert absence of dialysis evidence into a dialysis regimen.
The IV hydroxypropylbetadex issue has its own renal threshold. The selected active-drug guidance also leaves an exact-boundary gap at 10.
Before applying: Check route, formulation, age-appropriate renal assessment and the exact boundary; do not convert vehicle monitoring into an invented dose reduction.
Also check: PREVYMIS: renal evidence limit versus IV vehicle caution; PREVYMIS: IV-vehicle monitoring differs from active-drug dose adjustment
Rxlist source
GlobalRPh RX List - PREVYMIS
Product / population
Letermovir - PREVYMIS renal and intravenous-vehicle supplement; selected renal passages, not a complete prescribing monograph.
Renal measure
Cockcroft-Gault creatinine clearance (CrCl), mL/min. Pediatric renal assessment must be age appropriate.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
Adults with Cockcroft-Gault CrCl >10 mL/min need no renal adjustment. Pediatric use refers to a similar degree of impairment determined by an age-appropriate renal assessment, not automatic use of the adult equation. Safety in ESRD below 10, including dialysis, is unknown. With IV PREVYMIS at adult CrCl <50 or a comparable pediatric degree, hydroxypropyl betadex may accumulate; closely monitor serum creatinine. This excipient concern is formulation-specific. The printed >10 and <10 statements do not explicitly settle the exact value of 10.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
formulation scope
PREVYMIS: renal evidence limit versus IV vehicle caution
The adult no-adjustment passage does not extend below its studied clearance boundary. The IV vehicle adds a separate accumulation concern that is not the same as an oral dose adjustment.
How to use this: Retain the lower-function evidence limit, exact formulation and kidney monitoring together. Do not convert absence of dialysis evidence into a dialysis regimen.
PREVYMIS: IV-vehicle monitoring differs from active-drug dose adjustment
The IV hydroxypropylbetadex issue has its own renal threshold. The selected active-drug guidance also leaves an exact-boundary gap at 10.
How to use this: Check route, formulation, age-appropriate renal assessment and the exact boundary; do not convert vehicle monitoring into an invented dose reduction.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - Prevymis
Selected adult oral and IV renal guidance; IV vehicle warning kept route-specific.
Method: Estimated CrCl by Cockcroft-Gault, mL/min.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Selected adult oral and IV renal guidance; IV vehicle warning kept route-specific.
Renal method: Estimated CrCl by Cockcroft-Gault, mL/min. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No renal dosage adjustment is required above CrCl 10 mL/min. Safety below 10, including dialysis, is not established in this source. With IV PREVYMIS, CrCl below 50 can permit accumulation of the hydroxypropyl betadex vehicle; closely monitor serum creatinine. That vehicle warning must not be applied as an oral dose-reduction rule. The strict cutoff wording does not settle exactly 10 mL/min.
RDM33-rxlist-letermovir-prevymis-C1 · Source locator: Use in specific populations: renal impairment; IV vehicle precaution.
GlobalRPh-hosted RX List · Letermovir - PREVYMIS; selected renal source sections only, not a complete prescribing monograph.
Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
In adults with CrCl >10 mL/min, renal dose adjustment is not required. The dosing section states insufficient data to recommend dosing at CrCl <=10 mL/min or on dialysis. With intravenous PREVYMIS and CrCl <50 mL/min, accumulation of the hydroxypropyl betadex vehicle may occur; closely monitor serum creatinine. The oral and intravenous routes must therefore retain different formulation cautions. This selected adult statement is not a pediatric age/weight regimen.
RDM47-rxlist-letermovir-prevymis-b92f4e6efd-C1 · Source locator: Dosage: renal impairment; Use in Specific Populations 8.6; Clinical Pharmacology renal studies.
GlobalRPh-hosted RX List · Letermovir - PREVYMIS renal and intravenous-vehicle supplement; selected renal passages, not a complete prescribing monograph.
Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min. Pediatric renal assessment must be age appropriate. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Adults with Cockcroft-Gault CrCl >10 mL/min need no renal adjustment. Pediatric use refers to a similar degree of impairment determined by an age-appropriate renal assessment, not automatic use of the adult equation. Safety in ESRD below 10, including dialysis, is unknown. With IV PREVYMIS at adult CrCl <50 or a comparable pediatric degree, hydroxypropyl betadex may accumulate; closely monitor serum creatinine. This excipient concern is formulation-specific. The printed >10 and <10 statements do not explicitly settle the exact value of 10.
Additional summaries stored on this page: 0 official-label, 3 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.